7Small E J, Halabis, Dawsonna, et al. Anti - androgen withdrawal a- lone or in combination with ketoconazole in androgen - independ- ent prostate cancer patients:a phase Ⅲ trial( CALGB 8583 ) [ J ]. J Clin Onco1,2004,22 (6) : 1025 - 1033. 被引量：1
8De Bono JS, Logothetis C J, Molina A, et al. Abiraterone and in- creased Survival in metastatic prostate cancer[ J ]. N Engl J Med, 2011,364 (21) : 1995 - 2005. 被引量：1
9Rawlinson A, Mohammed A, Beatty J, et al. The role of abiraterone in the management of metastatic castration - resistant prostate cancer[ J ]. Expert Rev Anticancer Ther,2012,12 (4) :429 - 437. 被引量：1
10Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalu- tamide in prostate cancer after chemotherapy [ J]. N Engl J Med, 2012,367(13) :1187 - 1197. 被引量：1
5Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer. An overview of the randomised trials. Lancet, 2000, 355: 1491-1498. 被引量：1
6Schellhammer PF, Sharifir R, Block NL, et al. Clinical benefits of Bicalutamide compared with Flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology, 1997, 50: 330-336. 被引量：1
7Kolvenbag GJ, Blackledge GR, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate, 1998, 34: 61-72. 被引量：1
8Iversen P, Tyrrell CJ, Kaisary AV. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6. 3 years of followup. J Urol, 2000, 164: 1579-1582. 被引量：1
9Wirth MP, See WA, McLeod DG, et al. Bicalutamide 150mg in addition to standard care in patients with localized or locally advanced prostate cancer: results form the second analysis of the early prostate cancer program at median follow up of 5.4 years. J Urol, 2004, 172: 1865-1870. 被引量：1
